Cytokinetics, Inc. (NASDAQ: CYTK) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.36 million.

Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.

Earnings Guidance